{"id":"chimerivax-je-japanese-encephalitis-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine combines the attenuated yellow fever 17D vaccine strain with genes encoding the prM and E surface proteins of Japanese encephalitis virus. This chimeric approach leverages the well-established safety and immunogenicity of the YF 17D backbone while presenting JE-specific antigens to elicit both humoral and cellular immune responses against Japanese encephalitis virus.","oneSentence":"ChimeriVax-JE is a live attenuated chimeric vaccine that uses a yellow fever virus backbone expressing Japanese encephalitis virus envelope proteins to induce protective immunity against Japanese encephalitis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:39.091Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Japanese encephalitis prevention in endemic and at-risk populations"}]},"trialDetails":[{"nctId":"NCT00735644","phase":"PHASE3","title":"Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-08","conditions":"Japanese Encephalitis, Hepatitis A","enrollment":1200},{"nctId":"NCT00621764","phase":"PHASE2","title":"Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-03","conditions":"Japanese Encephalitis, Hepatitis A","enrollment":300},{"nctId":"NCT00314132","phase":"PHASE3","title":"Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-10","conditions":"Encephalitis, Japanese Encephalitis","enrollment":2004},{"nctId":"NCT00314145","phase":"PHASE3","title":"A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-11","conditions":"Japanese Encephalitis","enrollment":820},{"nctId":"NCT00981630","phase":"PHASE2","title":"Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-11","conditions":"Japanese Encephalitis","enrollment":128},{"nctId":"NCT00982137","phase":"PHASE2","title":"Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-07","conditions":"Japanese Encephalitis, Yellow Fever","enrollment":108},{"nctId":"NCT00441259","phase":"PHASE2","title":"Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-01","conditions":"Japanese Encephalitis","enrollment":96},{"nctId":"NCT00319592","phase":"PHASE2","title":"A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-05","conditions":"Japanese Encephalitis","enrollment":60},{"nctId":"NCT00981175","phase":"PHASE2","title":"A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-04","conditions":"Encephalitis, Japanese Encephalitis","enrollment":202}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ChimeriVax™"],"phase":"phase_3","status":"active","brandName":"ChimeriVax-JE, Japanese Encephalitis vaccine","genericName":"ChimeriVax-JE, Japanese Encephalitis vaccine","companyName":"Sanofi","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"ChimeriVax-JE is a live attenuated chimeric vaccine that uses a yellow fever virus backbone expressing Japanese encephalitis virus envelope proteins to induce protective immunity against Japanese encephalitis. Used for Japanese encephalitis prevention in endemic and at-risk populations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}